Guy Young/LinkedIn
Dec 13, 2025, 08:59
World Federation of Hemophilia: Eptacog Beta in Severe Bleeds – Insights From PERSEPT Trials
World Federation of Hemophilia shared on LinkedIn:
”Severe bleeds in hemophilia with inhibitors remain a major challenge. Post hoc analysis of the PERSEPT 1 and 2 trials highlights how eptacog beta can offer effective treatment options when they’re needed most.”
Read the full article here.
Article: Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials
Authors: Guy Young, Johnny Mahlangu, Lisa N. Boggio, Manuel Carcao, Yesim Dargaud, Miguel Escobar, Adam Giermasz, Cédric Hermans, Philip Kuriakose, Wolfgang Miesbach, Danielle Nance, Amina Rafique, Robert F. Sidonio Jr., Kateryna V. Vilchevska, Michael Wang, Steven W. Pipe

Stay updated with Hemostasis Today.
Adam Giermasz
Amina Rafique
bleeding disorders
Cedric Hermans
Danielle Nance
Eptacog Beta
Guy Young
Health
Hemophilia
Hemostasis Today
inhibitors
Johnny Mahlangu
Kateryna V. Vilchevska
Lisa N. Boggio
Manuel Carcao
Medicine
Michael Wang
Miguel Escobar
Philip Kuriakose
Robert F. Sidonio Jr.
Steven W. Pipe
WFH
Wolfgang Miesbach
World Federation of Hemophilia
Yesim Dargaud
-
Jan 31, 2026, 16:35IV Thrombolysis Does Not Improve Vision in Acute CRAO: Ahmed Koriesh on TenCRAOS Study
-
Jan 31, 2026, 16:24Joyce John Chalakkal: The Dangerous Area of The Face….
-
Jan 31, 2026, 16:04Rayya Saadiq Reflects On Qatar Health Congress 2026
-
Jan 31, 2026, 15:12Amar Raval on Oral Thin Film Drug Delivery Systems for Thrombosis Therapy
-
Jan 31, 2026, 14:40Heghine Khachatryan on WFH’s Call to Advance Health Equity for People with Bleeding Disorders
-
Jan 31, 2026, 14:10Emilia Arturo: Snake Venom, Clotting, and CryoEM!
-
Jan 31, 2026, 08:13Ming Y Lim On The Value of National Mentorship
-
Jan 31, 2026, 06:37Christian Schulze Presents The Post-Hoc Analysis of the DanGer Shock Trial
-
Jan 31, 2026, 06:27Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial